Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
This study is not yet open for participant recruitment.
Verified October 2012
by Sound Pharmaceuticals, Incorporated
Study NCT01451853 Information provided by Sound Pharmaceuticals, Incorporated
First Received on October 7, 2011. Last Updated on October 14, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung Cancer
Head and Neck Cancer
Hearing Loss
Ototoxicity
Tinnitus
Neuropathy
Additional conditions recognized in this trial
Deafness
Head and Neck Neoplasms
Lung Neoplasms
More general conditions related to this trial
Ear Diseases
Hearing Disorders
Lung Diseases
Neoplasms
Neoplasms by Site
Nervous System Diseases
Neurologic Manifestations
Otorhinolaryngologic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Sensation Disorders
Signs and Symptoms
Thoracic Neoplasms
Interventions listed in this trial
SPI-1005 Low Dose
SPI-1005 Middle dose
SPI-1005 High Dose
Placebo
Additional drug interventions recognized in this trial
Ebselen
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Ulcer Agents
Antioxidants
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Sound Pharmaceuticals, Incorporated
VA Puget Sound Health Care System
Back to top of Main Content
